what happens when you switch from tirzepatide to semaglutide Switching Semaglutide: to Expect Early Dose Escalation of Tirzepatide

Palmitoylation of gephyrin controls receptor clustering and plasticity of GABAergic synapses

Because lean mass supports metabolic rate and metabolic rate supports long-term weight stability, preserving muscle becomes one of the most important factors in maintaining results

Finally, rapid weight loss without nutritional monitoring or physical activity support can deplete lean muscle mass and trigger micronutrient deficiencies that persist after treatment ends

In SAXENDA clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving SAXENDA (4.8%) than placebo (1.4%)

Lim C-E, Pasternak B, Eliasson B, Danaei G, Ueda P (2022) Use of sodiumglucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes

Recently, the introduction of highly effective glucagon-like peptide-1 (GLP-1) receptor agonists has led to increased utilization of obesity medications in this population